Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

François-Xavier Lescure(Inserm), Stéphane Doucet(Centre Hospitalier de l’Université de Montréal), Owen Hagino, Carlos M. Ibarrola, Alessandra Martins Bales, Peter K. Wung(Sanofi (United States)), Darío Scublinsky, Madéleine Durand(Université de Montréal), Yael Pere, Jennifer Sloane Lazar(Sanofi (United States)), Javier P. Silvio, Juvêncio José Duailibe Furtado, Graziela Denardin Luckemeyer, Marco A. Solis Aramayo, Hugo Chapdelaine, Erica A. Miyazaki, Celso A. de Andrade, Valéria Telles, Sara Mohrbacher, Maria A. Iannantuono, Daniela Catarino, Marianna M. Lago, Ana Caroline Coutinho Iglessias, Ricardo Vipich, Elie Fiss(Faculdade de Medicina do ABC), Hitoshi Honda(Tokyo Metropolitan Tama Medical Center), Emilia Liana Falcone(Montreal Clinical Research Institute), Me‐Linh Luong(Université de Montréal), Ignacio J. Bazzalo, Adilson W. Cavalcante, Nelson Ribeiro Filho, Marcelo Martín Casas, Victor Augusto Hamamoto Sato, Leopoldo Tosi Trevelin, Francini Guerra Correa, Andrea E. Duarte, Antonio Baylao, Sebastián A. Núñez(Fundación Centro de Estudios Infectológicos), María Celia Cuesta, Rodrigo Boldo, Robert Fowler(Sunnybrook Health Science Centre), Daniel Wagner de Castro Lima Santos(D’Or Institute for Research and Education), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Suzana M. Lobo(Faculdade de Medicina de São José do Rio Preto), Luana Machado, Genming Shi(Sanofi (United States)), Pablo Fernández, Maysa B. Alves, Paula Borges, Naimish Patel(Sanofi (United States))
The Lancet Respiratory Medicine
March 7, 2021
Cited by 248


Related Papers